Search Thermo Fisher Scientific
Search Thermo Fisher Scientific
Preeclampsia is a life-threatening hypertensive disorder occurring during pregnancy which affects 3-4% of all pregnancies in the U.S.1 The condition most often occurs after 20 weeks of gestation and can only be cured by delivery of the baby.2 Preeclampsia contributes largely to maternal and fetal morbidity and mortality.
Placental biomarkers, sFlt-1 and PlGF, play a pivotal role in the risk assessment and clinical management of preeclampsia.
Experience the confidence that comes with our complete solution, backed by years of expertise and unwavering commitment to delivering excellence in prenatal care.
1. Burwick RM, Rodriguez MH. Angiogenic Biomarkers in Preeclampsia. Obstet Gynecol. 2024 Apr 1;143(4):515-523.
2. Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin Summary, Number 222. Obstetrics and Gynecology. 2020;135(6):1492-1495.
Thermo Fisher Scientific products are distributed globally and their uses, applications, indications, claims and availability of products in each country depend on local regulatory marketing authorization status, please consult the Instructions For Use (IFU) available in your country.
© 2024 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. B·R·A·H·M·S is a registered trademark of B·R·A·H·M·S GmbH.
KRYPTOR and TRACE are trademarks of Cisbio Bioassays, licensed for use by B·R·A·H·M·S GmbH, a part of Thermo Fisher Scientific. Nobel Prize is a registered trademark of the Nobel Foundation.